Archive: 16/11/2016

Controversial drug approval stirs deep concerns—and hope

In September, the Food and Drug Administration approved Exondys, a controversial treatment for Duchenne muscular dystrophy based on tenuous data from just 12 patients. The cover story in Chemical & Engineering News (C&EN), ...

page 4 from 10